Fulcrum Discontinues pociredir Development, Shares Plunge 49%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Source: stocktwits
- Regulatory Feedback Impact: On May 28, Fulcrum received meeting minutes from the FDA indicating serious concerns about the benefit-risk profile of pociredir, leading to the decision to discontinue its development, resulting in the loss of its only clinical asset and leaving the company without a near-term pipeline, severely impacting future business prospects.
- Stock Price Volatility: Following the announcement of the discontinuation, Fulcrum's shares plummeted 49% in after-hours trading, reflecting extreme market pessimism regarding the company's outlook, which could lead to further capital erosion and investor confidence issues.
- Strategic Review Initiated: Fulcrum has launched a comprehensive strategic review to explore alternatives, including mergers and acquisitions, aimed at maximizing shareholder value, demonstrating the company's response strategy amid significant challenges, though no specific timeline has been set, increasing uncertainty.
- Market Sentiment Shift: Despite the stock price decline, retail sentiment around Fulcrum on Stocktwits shifted from 'bearish' to 'bullish', with message volume rising from 'low' to 'normal', indicating some investors' optimism about potential future transactions, although overall market sentiment remains cautious.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FULC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FULC
Wall Street analysts forecast FULC stock price to rise
11 Analyst Rating
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 6.420
Low
7.00
Averages
16.80
High
25.00
Current: 6.420
Low
7.00
Averages
16.80
High
25.00
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulcrum Discontinues pociredir Development, Shares Plunge 49%
- Regulatory Feedback Impact: On May 28, Fulcrum received meeting minutes from the FDA indicating serious concerns about the benefit-risk profile of pociredir, leading to the decision to discontinue its development, resulting in the loss of its only clinical asset and leaving the company without a near-term pipeline, severely impacting future business prospects.
- Stock Price Volatility: Following the announcement of the discontinuation, Fulcrum's shares plummeted 49% in after-hours trading, reflecting extreme market pessimism regarding the company's outlook, which could lead to further capital erosion and investor confidence issues.
- Strategic Review Initiated: Fulcrum has launched a comprehensive strategic review to explore alternatives, including mergers and acquisitions, aimed at maximizing shareholder value, demonstrating the company's response strategy amid significant challenges, though no specific timeline has been set, increasing uncertainty.
- Market Sentiment Shift: Despite the stock price decline, retail sentiment around Fulcrum on Stocktwits shifted from 'bearish' to 'bullish', with message volume rising from 'low' to 'normal', indicating some investors' optimism about potential future transactions, although overall market sentiment remains cautious.
See More
Biotech Stocks Show Strong Pre-Market Moves
- Bluejay Diagnostics Surge: Bluejay Diagnostics, Inc. (BJDX) skyrocketed 193% to $6.35 in pre-market trading, indicating strong market demand for its products, which may attract more investor interest in its future developments.
- Picard Medical Significant Growth: Picard Medical, Inc. (PMI) saw a 95% increase to $0.33, reflecting positive investor sentiment towards its new products or services, potentially providing the company with additional funding support.
- Sunshine Biopharma Continues Upward Trend: Sunshine Biopharma, Inc. (SBFM) rose 26% to $3.00 in pre-market trading, suggesting optimistic market sentiment regarding its R&D progress, which could facilitate an expansion of its market share.
- Fulcrum Therapeutics Major Decline: Fulcrum Therapeutics, Inc. (FULC) plummeted 52% to $3.06 in pre-market trading, indicating investor concerns about its financial health, which may limit its ability to secure future financing.
See More
Fulcrum Therapeutics Abandons Sickle-Cell Drug Development Amid FDA Concerns
- Stock Plunge: Fulcrum Therapeutics' shares plummeted 50% in premarket trading on Tuesday, reflecting strong market reaction to the company's decision to abandon its experimental sickle-cell disease drug following FDA cancer risk concerns, leading to a significant loss of investor confidence.
- Drug Development Setback: The company aimed to use pociredir to increase fetal hemoglobin levels for treating sickle-cell disease, but the FDA indicated that all drugs targeting the PRC2 protein complex carry similar malignancy risks, compounding the challenges in drug development.
- Strategic Shift: Fulcrum announced it would explore strategic options, including a potential sale or merger, and has begun cost-cutting measures to preserve cash, with current cash and investments totaling $333.3 million, indicating the company's response strategy amid significant challenges.
- Clinical Trial Insights: Despite the FDA's safety concerns, Fulcrum emphasized that no new safety issues had emerged in clinical trials, and pociredir demonstrated increases in fetal hemoglobin, which could help alleviate disease severity in sickle-cell patients.
See More
Fulcrum Therapeutics Halts pociredir Development Amid FDA Safety Concerns
- Development Halted: Fulcrum Therapeutics announced the discontinuation of its lead asset pociredir for sickle cell disease due to safety concerns raised by the FDA, resulting in a nearly 50% drop in stock value during after-hours trading.
- Regulatory Feedback Impact: The FDA highlighted an unfavorable benefit-risk profile for pociredir during a recent meeting, particularly in light of blood cancer risks associated with Tazverik, leaving no viable regulatory path for further clinical development.
- Strategic Review Initiated: Concurrently, the company announced a strategic alternatives review program, including a potential sale, to address current financial pressures and plans to sharply cut operating expenditures to preserve capital amid uncertainty.
- CEO Statement: CEO Alex Sapir stated that after a thorough review of regulatory feedback and available data, the difficult decision to halt pociredir's development reflects significant implications for the company's future trajectory.
See More
Fulcrum Discontinues Pociredir Program Amid FDA Concerns
- Program Termination: Fulcrum Therapeutics announced the discontinuation of its lead program Pociredir due to FDA feedback regarding concerns over secondary malignancies associated with Tazverik, leading to significant challenges in the company's R&D efforts and a complete withdrawal from the global market.
- Stock Plunge: Following the announcement, Fulcrum's stock plummeted 51.25% to $3.13 in after-hours trading, reflecting extreme investor pessimism about the company's future prospects, which could adversely affect its ability to raise funds and maintain market confidence.
- Strategic Review Initiated: Fulcrum stated it will explore strategic alternatives, including mergers, acquisitions, or other strategic transactions, aiming to identify new growth opportunities despite facing significant R&D hurdles, indicating a proactive approach to restore investor confidence through potential restructuring.
- Financial Position: As of March 31, 2026, Fulcrum had $333.3 million in cash and cash equivalents, providing the company with some financial flexibility to navigate future strategic adjustments despite the pressure from the program termination.
See More
Fulcrum Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: Fulcrum Therapeutics granted 55,500 stock options to two new employees at an exercise price of $7.02 per share, reflecting the company's commitment to attracting talent to enhance its research and development capabilities.
- Incentive Plan Context: This grant is made under the company's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4), demonstrating Fulcrum's strategic planning in talent acquisition to boost overall competitiveness.
- Option Structure Design: The options have a ten-year term with a four-year vesting schedule, where 25% vests on the first anniversary and 6.25% vests quarterly thereafter, which not only incentivizes long-term employee retention but also ensures team stability to support ongoing business growth.
- Company Strategic Positioning: Fulcrum focuses on developing small molecules to improve the lives of patients with rare genetic diseases, particularly targeting sickle cell disease, showcasing the company's innovative capabilities and market potential in the biopharmaceutical sector, thereby reinforcing its industry position.
See More
Fulcrum Discontinues pociredir Development, Shares Plunge 49%
- Regulatory Feedback Impact: On May 28, Fulcrum received meeting minutes from the FDA indicating serious concerns about the benefit-risk profile of pociredir, leading to the decision to discontinue its development, resulting in the loss of its only clinical asset and leaving the company without a near-term pipeline, severely impacting future business prospects.
- Stock Price Volatility: Following the announcement of the discontinuation, Fulcrum's shares plummeted 49% in after-hours trading, reflecting extreme market pessimism regarding the company's outlook, which could lead to further capital erosion and investor confidence issues.
- Strategic Review Initiated: Fulcrum has launched a comprehensive strategic review to explore alternatives, including mergers and acquisitions, aimed at maximizing shareholder value, demonstrating the company's response strategy amid significant challenges, though no specific timeline has been set, increasing uncertainty.
- Market Sentiment Shift: Despite the stock price decline, retail sentiment around Fulcrum on Stocktwits shifted from 'bearish' to 'bullish', with message volume rising from 'low' to 'normal', indicating some investors' optimism about potential future transactions, although overall market sentiment remains cautious.
See More
Biotech Stocks Show Strong Pre-Market Moves
- Bluejay Diagnostics Surge: Bluejay Diagnostics, Inc. (BJDX) skyrocketed 193% to $6.35 in pre-market trading, indicating strong market demand for its products, which may attract more investor interest in its future developments.
- Picard Medical Significant Growth: Picard Medical, Inc. (PMI) saw a 95% increase to $0.33, reflecting positive investor sentiment towards its new products or services, potentially providing the company with additional funding support.
- Sunshine Biopharma Continues Upward Trend: Sunshine Biopharma, Inc. (SBFM) rose 26% to $3.00 in pre-market trading, suggesting optimistic market sentiment regarding its R&D progress, which could facilitate an expansion of its market share.
- Fulcrum Therapeutics Major Decline: Fulcrum Therapeutics, Inc. (FULC) plummeted 52% to $3.06 in pre-market trading, indicating investor concerns about its financial health, which may limit its ability to secure future financing.
See More
Fulcrum Therapeutics Abandons Sickle-Cell Drug Development Amid FDA Concerns
- Stock Plunge: Fulcrum Therapeutics' shares plummeted 50% in premarket trading on Tuesday, reflecting strong market reaction to the company's decision to abandon its experimental sickle-cell disease drug following FDA cancer risk concerns, leading to a significant loss of investor confidence.
- Drug Development Setback: The company aimed to use pociredir to increase fetal hemoglobin levels for treating sickle-cell disease, but the FDA indicated that all drugs targeting the PRC2 protein complex carry similar malignancy risks, compounding the challenges in drug development.
- Strategic Shift: Fulcrum announced it would explore strategic options, including a potential sale or merger, and has begun cost-cutting measures to preserve cash, with current cash and investments totaling $333.3 million, indicating the company's response strategy amid significant challenges.
- Clinical Trial Insights: Despite the FDA's safety concerns, Fulcrum emphasized that no new safety issues had emerged in clinical trials, and pociredir demonstrated increases in fetal hemoglobin, which could help alleviate disease severity in sickle-cell patients.
See More
Fulcrum Therapeutics Halts pociredir Development Amid FDA Safety Concerns
- Development Halted: Fulcrum Therapeutics announced the discontinuation of its lead asset pociredir for sickle cell disease due to safety concerns raised by the FDA, resulting in a nearly 50% drop in stock value during after-hours trading.
- Regulatory Feedback Impact: The FDA highlighted an unfavorable benefit-risk profile for pociredir during a recent meeting, particularly in light of blood cancer risks associated with Tazverik, leaving no viable regulatory path for further clinical development.
- Strategic Review Initiated: Concurrently, the company announced a strategic alternatives review program, including a potential sale, to address current financial pressures and plans to sharply cut operating expenditures to preserve capital amid uncertainty.
- CEO Statement: CEO Alex Sapir stated that after a thorough review of regulatory feedback and available data, the difficult decision to halt pociredir's development reflects significant implications for the company's future trajectory.
See More
Fulcrum Discontinues Pociredir Program Amid FDA Concerns
- Program Termination: Fulcrum Therapeutics announced the discontinuation of its lead program Pociredir due to FDA feedback regarding concerns over secondary malignancies associated with Tazverik, leading to significant challenges in the company's R&D efforts and a complete withdrawal from the global market.
- Stock Plunge: Following the announcement, Fulcrum's stock plummeted 51.25% to $3.13 in after-hours trading, reflecting extreme investor pessimism about the company's future prospects, which could adversely affect its ability to raise funds and maintain market confidence.
- Strategic Review Initiated: Fulcrum stated it will explore strategic alternatives, including mergers, acquisitions, or other strategic transactions, aiming to identify new growth opportunities despite facing significant R&D hurdles, indicating a proactive approach to restore investor confidence through potential restructuring.
- Financial Position: As of March 31, 2026, Fulcrum had $333.3 million in cash and cash equivalents, providing the company with some financial flexibility to navigate future strategic adjustments despite the pressure from the program termination.
See More
Fulcrum Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: Fulcrum Therapeutics granted 55,500 stock options to two new employees at an exercise price of $7.02 per share, reflecting the company's commitment to attracting talent to enhance its research and development capabilities.
- Incentive Plan Context: This grant is made under the company's 2022 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4), demonstrating Fulcrum's strategic planning in talent acquisition to boost overall competitiveness.
- Option Structure Design: The options have a ten-year term with a four-year vesting schedule, where 25% vests on the first anniversary and 6.25% vests quarterly thereafter, which not only incentivizes long-term employee retention but also ensures team stability to support ongoing business growth.
- Company Strategic Positioning: Fulcrum focuses on developing small molecules to improve the lives of patients with rare genetic diseases, particularly targeting sickle cell disease, showcasing the company's innovative capabilities and market potential in the biopharmaceutical sector, thereby reinforcing its industry position.
See More
